Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting

June 8th, 2012
Piramal Imaging SA, a subsidiary of Piramal Healthcare Limited [NSE: PIRHEALTH, BSE: 500302], will present data on several compounds from its molecular imaging portfolio at the Society of Nuclear Medicine's 59th annual meeting in Miami Beach, Fla., from June 9 - 13. Data from five florbetaben studies will be featured, including results from a pivotal Phase III trial which will provide the basis for regulatory submission later this year.

Earlier this spring, Piramal Imaging was formed through the acquisition of worldwide rights to the molecular imaging research and development portfolio of Bayer Pharma AG. Florbetaben, a late-stage amyloid imaging agent being studied as a potential tool to aid in the diagnosis and assessment of Alzheimer's disease, is the lead compound in the portfolio.

Historically, the only way to definitively diagnose Alzheimer's disease has been after death – at autopsy – through analysis and identification of beta-amyloid in brain tissue. The global Phase III trial employed a unique and rigorous study design comparing in vivo brain positron emission tomography (PET) imaging with florbetaben to post-mortem analysis of the brain tissue. Another study compared florbetaben scans of people with mild cognitive impairment (MCI) over time to assess their risk of developing Alzheimer's disease.

"What better way to introduce Piramal Imaging to the nuclear medicine community," says Dr. Ludger M. Dinkelborg, CEO Piramal Imaging. "We believe we have the richest molecular imaging portfolio in the industry today, and the range of research we are presenting here reflects the depth, diversity and clinical relevance of our pipeline." Before co-founding Piramal Imaging, Dr. Dinkelborg served as Head of Diagnostic Imaging Research and Head of Molecular Imaging at Bayer Healthcare.

Piramal Imaging is developing an innovative and proprietary tracer portfolio to address major clinical needs in Alzheimer's disease, prostate cancer, lung cancer, liver cancer, and cardiovascular disease.

"Our goal is to be a leader in molecular imaging through increased diagnostic accuracy of serious medical conditions to improve patient care," says Dr. Swati A. Piramal, Director, Piramal Healthcare Limited. "On a parallel track with our aggressive clinical development program, we are taking the necessary steps toward bringing our tracers to market through the formation of strategic partnerships." Dr. Piramal was recently elected to the Harvard Board of Overseers and also serves on the Dean's Advisory Board of both the Harvard School of Public Health and Harvard Business School.

At this meeting, research on several of the company's pipeline compounds will be featured, including:

NOTE TO EDITORS: All data is embargoed until the date/time of presentation.

Florbetaben

Multicentre phase 3 trial on florbetaben for β-amyloid brain PET in Alzheimer disease [Abstract #41]

Oral Presentation: Neuroscience Miscellaneous & New Approaches

Sunday, June 10, 1:57 PM - 2:09 PM, Room B217/218

Presenter: Osama Sabri, University of Leipzig, Leipzig, Germany

Longitudinal assessment of cerebral amyloid-β deposition in APP-Swe mice with [18F]florbetaben PET [Abstract #92]

Oral Presentation: Brain Imaging Council Young Investigator Award Symposium

Sunday, June 10, 5:03 PM - 5:15 PM, Room B217/218

Presenter: Axel Rominger, University of Munich, Munich, Germany

Partial volume effect correction of florbetaben β-amyloid (Aβ) PET data improves discrimination between Alzheimer's disease (AD) patients and healthy volunteers (HVs) [Abstract #146]

Oral Presentation: Quantifying Brain Amyloid Signal - Methods & Challenges

Monday, June 11, 10:24 AM - 10:36 AM, Room B217/218

Presenter: Henryk Barthel, University of Leipzig, Leipzig, Germany

A two-year longitudinal assessment of Aβ deposition in MCI with 18F-Florbetaben [Abstract #148]

Oral Presentation: Quantifying Brain Amyloid Signal - Methods & Challenges

Monday, June 11, 10:48 AM - 11:00 AM, Room B217/218

Presenter: Kevin Ong, Centre for PET, Austin Health, Melbourne, VIC, Australia

In vivo PET imaging of β-amyloid plaques in an APP/PS1 mouse model of Alzheimer's disease: Comparison of [18F]FIBT and [18F]Florbetaben with [11C]PiB [Abstract #1630]

Poster Presentation: Probes for Neuroimaging

Sunday, June 10, 7:04 PM - 7:06 PM, Exhibit Hall A-B

Presenter: Behrooz Hooshyar Yousefi, Technische Universität München, Munich, Germany

FSPG

Correlation of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate ([18F]FSPG) uptake by positron emission tomography (PET) with immunohistochemical expression of system xC- and CD44 in cancer patients [Abstract #219]

Oral Presentation: Basic Science (Oncology); Tumor Characterization & Microenvironment

Monday, June 11, 5:18 PM - 5:30 PM, Room B118/119

Presenter: Dae Hyuk Moon, University of Ulsan College of Medicine, Seoul, Republic of Korea

Evaluation of the 18F L-glutamate derivative 18F-FSPG (BAY 94-9392) in lymphoma and colon cancer patients [Abstract #1126]

Poster Presentation: Meet the Author Poster Session; Basic Science (Oncology)

Monday, June 11, 2:30 PM - 4:00 PM, Exhibit Hall A-B

Presenter: Meena Kumar, Stanford University Medical Center, Palo Alto, California, USA

Evaluation of the 18F-labeled L-glutamate derivative 18F-FSPG (BAY 94-9392) in brain and head and neck cancer patients [Abstract #274]

Oral Presentation: Basic Science (Oncology); Novel Imaging Agents - Clinical

Tuesday, June 12, 8:36 AM - 8:48 AM, Room B118/119

Presenter: Meena Kumar, Stanford University Medical Center, Palo Alto, California, USA

Characterization of physiological 18F-FSPG uptake in healthy volunteers: Kinetics and biodistribution [Abstract #555]

Oral Presentation: Technological Advances, Methodology, Quantification

Wednesday, June 13, 10:33 AM - 10:45 AM, Room B118/119

Presenter: Camila Mosci, Stanford University, Palo Alto, California, USA

Ga68-Bombesin

Preclinical validation of the Ga-68-Bombesin Antagonist BAY 86-7548 for a Phase I Study in Prostate Cancer Patients [Abstract #177]

Oral Presentation: Prostate

Monday, June 11, 12:30 PM - 12:42 PM, Room B214

Presenter: Sandra Borkowski, Global Drug Discovery, Bayer Healthcare, Berlin, Germany

Radiosynthesis and pre-clinical evaluation of Al18F labeled bombesin antagonist: Promising tracer for prostate cancer imaging [Abstract #1732]

Poster Presentation: Special Meet the Author Poster Session; Probes for Oncology

Sunday, June 10, 6:30 PM - 8:00 PM, Exhibit Hall A-B

Presenter: Svetlana Selivanova, Center for Radiopharmaceutical Sciences, ETH Zurich, Zurich, Switzerland

DFMT

Clinical investigation of dynamic PET/CT imaging using O-([18F]fluoromethyl)-D-tyrosine (D-18F-FMT, BAY 86-9596) in oncological patients [Abstract #1676]

Poster Presentation: Special Meet the Author Poster Session; Probes for Oncology

Sunday, June 10, 6:30 PM - 8:00 PM, Exhibit Hall A-B

Presenter: Irene Burger, University Hospital, Zurich, Switzerland

Comparison of PET/CT images with a novel tracer O-([18F]fluoromethyl)-D-tyrosine (D-18F-FMT, BAY 86-9596) with LAT1 immunohistochemical staining in patients with non-small cell lung cancer or head and neck squamous cell carcinoma [Abstract #1677]

Poster Presentation: Special Meet the Author Poster Session; Probes for Oncology

Sunday, June 10, 6:30 PM - 8:00 PM, Exhibit Hall A-B

Presenter: Irene Burger, University Hospital, Zurich, Switzerland

Provided by Ketchum New York

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Chikungunya fever identified in the United States

(HealthDay)—Chikungunya fever is being seen in travelers returning to the United States from affected regions and should be considered as a diagnosis for febrile travelers, according to an ideas and opinions ...

Big new iPhone brings Apple more profit

Apple's largest iPhone is selling for $100 more than its other new model, but a new report says it costs Apple only $15.50 more to make the more expensive version.